J-max Dhc

J-max Dhc

J-max Dhc Recall

Get an alert when a recall is issued.

Questions & Answers

Side Effects & Adverse Reactions

General:  Considerable caution should be exercised in patients with hypertension, diabetes mellitus, ischemic heart disease, hyperthyroidism, increased intraocular pressure, and prostatic hypertrophy.  The elderly (60 years and older) are more likely to exhibit adverse reactions.

Usage in Ambulatory Patients:  Dihydrocodeine may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks such as driving a car or operating machinery.

Respiratory Depression:  Respiratory depression is the most dangerous acute reaction produced by opioid agonist preparations, although it is rarely severe with usual doses.  Opioids decrease the respiratory tidal volume, minute ventilation, and sensitivity to carbon dioxide.  Respiratory depression occurs most frequently in elderly or dibilitated patients, usually after large initial doses in non-tolerant patients, or when opioids are given in conjunction with other agents that depress respiration.  This combination product should be used with caution in patients with significant chronic obstructive pulmonary disease or cor pulmonale and in patients with a substantially decreased respiratory reserve, hypoxia, hypercapnia, or respiratory depression.

Hypertensive Effect:  Dihydrocodeine, like all opioid analgesics, may cause hypotension in patients whose ability to maintain blood pressure has been compromised by a depleted blood volume or who received concurrent therapy with drugs such as phenothiazine or other agents which compromise vasomotor tone.  This product may produce orthostatic hypotension in ambulatory patients.  This combination product should be administered with caution to patients with circulatory shock since vasodilation produced by the drug may further reduce cardiac output and blood pressure.

Dependence:  Dihydrocodeine can produce drug dependence of the codeine type and has the potential of being abused.  This product should be prescribed and administered with the appropriate degree of caution (See Drug Abuse and Dependence section).

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

This product is indicated for the temporary relief of nasal congestion and dry, non-productive cough associated with upper respiratory tract infections and allergies.

History

There is currently no drug history available for this drug.

Other Information

CIII

J-MAX DHC
Liquid
Rx Only

DESCRIPTION

Each 5 mL (one teaspoonful) for oral administration contains:
Dihydrocodeine Bitartrate..............................7.5 mg
(WARNING-May be habit forming)
Guaifenesin.................................................100 mg

This product contains the following inactive ingredients:
Glycerin, Propylene Glycol, Sorbitol, Citric Acid, Sodium Citrate, Sodium Saccharin, Grape Flavor, FD&C Red #40,
FD&C Blue #1, Menthol Crystals, Purified Water.

This product contains ingredients of the following therapeutic classes:  Antitussive and Expectorant.

Dihydrocodeine Bitartrate is an antitussive with the chemical name Morphine-6-ol,4,5-epoxy-3-methoxy-17-methyl-,(5α,6α)-2,3-dihydroxybutanedioate (1:1) (salt).  It has the following structural formula:

Dihydrocodeine Bitartrate structural formula


Guaifenesin is an expectorant with the chemical name 1,2-Propanediol,3-(2-methoxyphenoxy)-,(±)-.  It has the following structural formula:

Guaifenesin structural formula


J-max Dhc Manufacturers


  • Jaymac Pharmaceuticals
    J-max Dhc (Dihydrocodeine Bitartrate, Guaifenesin) Liquid [Jaymac Pharmaceuticals]

Login To Your Free Account